medigraphic.com

2007, Number 1

<< Back Next >>

Arch Cardiol Mex 2007; 77 (1)

High-density lipoproteins (HDL) size and composition are modified in the rat by a diet supplemented with “Hass” avocado (Persea americana Miller)

Pérez MÓ, García HL

Language: Spanish
References: 33
Page: 17-24
PDF size: 116.06 Kb.


ABSTRACT

Purpose: To determine the effects of dietary avocado on HDL structure and their associated enzyme, paraoxonase 1 (PON1). Methods: Fifteen Wistar male rats received avocado as part of their daily meal (5 g by 17.5 g chow diet), keeping the caloric intake similar to the control group (n = 15) that received their usual chow diet. After 5 weeks, HDL were isolated by sequential ultracentrifugation and their size and chemical composition were analyzed. PON1 was determined in serum spectrophotometrically using phenylacetate as substrate. Results: Rats that received avocado had about 27% lower triglycerides plasma levels whereas their HDL-cholesterol was 17% higher as compared to control group. The mean HDL Stokes diameter was significantly lower in avocado group (11.71 ± 0.8 vs 12.27 ± 0.26 nm, in control group, p ‹ 0.05). The HDL size decrease was associated to a lower content of protein, particularly of apo AI, with a concomitant higher proportion of phospholipids in HDL isolated from avocado group. HDL structural modifications induced by avocado were not related to modifications of LCAT and PLTP activities, but occurred in parallel with higher serum levels of PON1 activity when compared to the controls (57.4 ± 8.9 vs 43.0 ± 5.6 µmol/min/mL serum, p ‹ 0.05). Conclusions: The inclusion of avocado in the diet decreased plasma triglycerides, increased HDL-cholesterol plasma levels and modified HDL structure. The latter effect may enhance the antiatherogenic properties of HDL since PON1 activity also increased as a consequence of avocado.


REFERENCES

  1. Assmann G, Schulte H, Von Eckardstein A, Huang Y: High-density lipoprotein cholesterol as a predictor of coronary heart disease risk: the PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996; 124: S11-S20.

  2. Shah PK, Kaul S, Nilsson J, Cercek B: Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins an idea whose time for testing is coming, part I. Circulation 2001; 104: 2376-2386.

  3. von Eckardstein A, Nofer JR, Assmann G: High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 2001; 21: 13-27.

  4. Nofer JR, Kehrel B, Fobker M, Levkau B, Assmann G, von Eckardstein A: HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis 2002; 161: 1-16.

  5. Oschry Y, Eisenberg S: Rat plasma lipoproteins: re-evaluation of a lipoprotein system in an animal devoid of cholesteryl ester transfer activity. J Lipid Res 1982; 23: 1099-1106.

  6. Sviridov D, Nestel P: Dynamics of reverse cholesterol transport: protection against atherosclerosis. Atherosclerosis 2002; 161: 245-254

  7. Skiner ER: High-density lipoprotein subclasses. Curr Opin Lipidol 1994; 5: 241-247.

  8. Lamarche B, Uffelman KD, Steiner G, Barrett PH, Lewis GF: Analysis of particle size and lipid composition as determinants of the metabolic clearance of human high density lipoproteins in a rabbit model. J Lip Res 1998; 39: 1162-1172.

  9. Pérez-Méndez O, Torres-Tamayo M, Posadas-Romero C, Vidaure Garcés V, Carreón-Torres E, Mendoza-Pérez E, et al: Abnormal HDL subclasses distribution in overweight children with insulin resistance or type 2 diabetes mellitus. Clin Chim Acta 2006, in press. Jul 14; [Epub ahead of print]

  10. Deakin S, Leviev I, Gomaraschi M, Calabresi L, Franceschini G, James RW: Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high affinity, saturable, desorption mechanism. J Biol Chem 2002; 277: 4301-4308.

  11. Kontush A, Chantepie S, Chapman MJ: Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler Thromb Vasc Biol 2003; 23: 1881-1888.

  12. Castro GR, Fielding CJ: Early incorporation of cell-derived cholesterol into pre-ß-migrating high density lipoprotein pathway. Biochemistry 1988; 27: 25-29.

  13. Aviram M, Hardak E, Vaya J, Mahmood S, Milo S, Hoffman A, et al: Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation 2000; 101: 2510-2517.

  14. Huesca C, Luc G, Duhal N, Lacroix B, Fruchart J, Pérez-Méndez O: Ciprofibrate increases synthesis and catabolism of HDL apo AI and AII in patients with hypertriglyceridemia (Abstract). Atherosclerosis suppl 2004; 5: 64.

  15. Carreón-Torres E, Juárez-Meavepena M, Cardoso-Saldana G, Gómez CH, Franco M, Fievet C, et al: Pioglitazone increases the fractional catabolic and production rates of high-density lipoproteins apo AI in the New Zealand white rabbit. Atherosclerosis 2005; 181: 233-240.

  16. Kuvin JT, Dave DM, Sliney KA, Mooney P, Patel AR, Kimmelstiel CD, et al: Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. Am J Cardiol 2006; 98: 743-745.

  17. Almario RU, Vonghavaravat V, Wong R, Kasim-Karakas SE: Effects of walnut consumption on plasma fatty acids and lipoproteins in combined hyperlipidemia. Am J Clin Nutr 2001; 74: 72-79.

  18. Ait-Yahia D, Madani S, Prost J, Bouchenak M, Belleville J: Fish protein improves blood pressure but alters HDL2 and HDL3 composition and tissue lipoprotein lipase activities in spontaneously hypertensive rats. Eur J Nutr 2005; 44: 10-17.

  19. Carranza-Madrigal J, Alvizouri-Muñoz M, Alvarado-Jiménez MR, Chávez-Carvajal F, Gómez M, Herrera JE: Effects of avocado on the level of blood lipids in patients with phenotype II and IV dyslipidemias. Arch Inst Cardiol Mex 1995; 65: 342-348.

  20. Lopez Ledesma R, Frati Munari AC, Hernandez Dominguez BC, Cervantes Montalvo S, Hernandez Luna MH, Juarez C, et al: Monounsaturated fatty acid (avocado) rich diet for mild hypercholesterolemia. Arch Med Res 1996; 27: 519-523.

  21. Alvizouri Muñoz M, Corral Cossio A., Rodríguez Barrón A, Chávez Carvajal F: El aceite de aguacate en la prevención de aterosclerosis experimental inducida con colesterol. Aterosc Prev Cardiov 2001; 4: 92-98.

  22. Huesca-Gómez C, Franco M, Luc G, Montano LF, Masso F, Posadas-Romero C, Perez-Mendez O: Chronic hypothyroidism induces abnormal structure of high-density lipoproteins and impaired kinetics of apolipoprotein A-I in the rat. Metabolism 2002; 51: 443-450.

  23. Lowry OH, Rosebrough HJ, Farr AL: Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193: 265-275.

  24. Chen C, Albers JJ: Characterization of proteoliposome containing apolipoprotein A-I: a new substrate for the measurement lecithin cholesterol acyltransferase activity. J Lipid Res 1982; 23: 680-691.

  25. Huesca-Gómez C, Carreón-Torres E, Nepomuceno-Mejía T, Sánchez-Solorio M, Galicia-Hidalgo M, Mejía AM, et al: Contribution of cholesteryl ester transfer protein and lecithin: cholesterol acyltranferase to HDL size distribution. Endocrin Res 2004; 30: 403-415.

  26. Pérez-Méndez O, Vanloo B, Decout A, Goethals M, Peelman F, Vandekerckhove J, et al: Contribution of the hydrophobicity gradient of an amphipathic peptide to its mode of association with lipids. Eur J Biochem 1998; 256: 570-579.

  27. Gan KN, Smolen A, Eckerson HW, La-Du BN: Purification of human serum paraoxonase/arylesterase. Drug Metab Dispos 1991; 19: 100-106.

  28. Pérez-Méndez O, Luc G, Posadas-Romero C: Concentraciones bajas de lipoproteínas de alta densidad (HDL) en plasma y enfermedad arterial coronaria. Arch Inst Cardiol Méx 2000; 70: 312-321.

  29. Perez-Mendez O, Bruckert E, Franceschini G, Duhal N, Lacroix B, Bonte JP, Sirtori C et al: Metabolism of apolipoproteins AI and AII in subjects carrying similar apoAI mutations, apoAI Milano and apoAI Paris. Atherosclerosis 2000; 148: 317-325.

  30. Elkhalil L, Majd Z, Bakir R, Perez-Mendez O, Castro G, Poulain P, et al: Fish-eye disease: structural and in vivo metabolic abnormalities of high-density lipoproteins. Metabolism 1997; 46: 474-483.

  31. Perez-Mendez O, Castro G, Fruchart J, Luc G: Kinetic and metabolic studies of apo A-I and apo A-II in a hypoalphalipoproteinemic patient (Abstract). Eur J Neurol (suppl 2) 1995; 2: 77.

  32. Morgan J, Carey C, Lincoff A, Capuzzi D: High-density lipoprotein subfractions and risk of coronary artery disease. Curr Atheroscler Rep 2004; 6: 359-365.

  33. Freedman DS, Otvos JD, Jeyarajah EJ, Barboriak JJ, Anderson AJ, Walker JA: Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease. Arterioscler Thromb Vasc Biol 1998; 18: 1046-1053.




2020     |     www.medigraphic.com